BlueCross BlueShield
Federal Employee Program
Federal Employee Program®
750 9th St NW
Washington, D.C. 20001
202.942.1000
Fax 202.942.1125

5.90.065

Section:	Prescription Drugs	**Effective Date:**	April 1, 2024
Subsection:	Topical Products	**Original Policy Date:**	September 1, 2023
Subject:	Izervay	**Page:**	1 of 4

Last Review Date: March 8, 2024

Izervay

Description

Izervay (avacincaptad pegol)

Background
Izervay (avacincaptad pegol) is an RNA aptamer, a PEGylated oligonucleotide that binds to and inhibits complement protein C5. By inhibiting C5, Izervay may prevent its cleavage to C5a and C5b thus decreasing membrane attack complex (MAC) formation (1).

Regulatory Status
FDA-approved indication: Izervay is a complement inhibitor indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) (1).

Izervay is contraindicated in ocular or periocular infections and in active intraocular inflammation (1).

Izervay carries warnings of endophthalmitis and retinal detachments, neovascular AMD, and increased intraocular pressure (IOP) (1).

The safety and effectiveness of Izervay in pediatric patients have not been established (1).

Related policies
Bevacizumab, Lucentis, Susvimo, VEGF Inhibitors

Policy

This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.

Izervay may be considered **medically necessary** if the conditions indicated below are met.

Izervay may be considered **investigational** for all other indications.

Prior-Approval Requirements

Age 18 years of age or older

Diagnosis

Patient must have the following:

Geographic atrophy (GA) secondary to age-related macular degeneration (AMD)

AND ALL of the following:

a. Prescriber agrees to monitor for endophthalmitis, retinal detachment, and neovascular AMD
b. **NO** ocular or periocular infection
c. **NO** active intraocular inflammation
d. **NOT** used in combination with Vascular Endothelial Growth Factor (VEGF) Inhibitors for ocular indications (see Appendix 1)

Prior – Approval *Renewal* Requirements

None

Policy Guidelines

Pre - PA Allowance

None

Prior - Approval Limits

Quantity 12 single-dose vials per affected eye

Duration 24 months

Prior – Approval *Renewal* Limits

None

Rationale

Summary

Izervay is indicated for the treatment of geographic atrophy secondary to age-related macular degeneration. Patients taking Izervay should be monitored for endophthalmitis and retinal detachments, neovascular AMD, and increased intraocular pressure. Izervay is contraindicated in patients with ocular or periocular infections and active intraocular inflammation (1).

Prior authorization is required to ensure the safe, clinically appropriate, and cost-effective use of Izervay while maintaining optimal therapeutic outcomes.

References

1. Izervay [package insert]. Parsippany, NJ: IVERIC bio, Inc.; August 2023.

Policy History

Date	Action
September 2023	Addition to PA
December 2023	Annual review
March 2024	Annual review

Keywords

This policy was approved by the FEP® Pharmacy and Medical Policy Committee on March 8, 2024 and is effective on April 1, 2024.

Appendix 1 - List of VEGF Inhibitors for Ocular Indications

Generic Name	Brand Name
aflibercept	Eylea
bevacizumab	Avastin
brolucizumab-dbll	Beovu
faricimab-svoa	Vabysmo
ranibizumab	Lucentis
ranibizumab	Susvimo